Source disclosure: January 29, 2026
CHUGAI PHARMACEUTICAL CO.,LTD. [4519.T]
TOKYO, Jan 29 (Pulse News Wire) – Chugai Pharmaceutical CO.,LTD. (4519.T) reported fourth-quarter revenue of ¥1.200 billion, marking a 21.8% increase from the previous quarter.
The company also forecast continued growth, projecting a 7.5% rise in annual revenue to ¥13.15 billion for fiscal year 2026. Operating profit surged 36.6% to ¥6,222 billion compared to the same period last year, driven by robust sales performance across domestic and international markets. For the fiscal year ending December 2025, Chugai expects its operating margin to remain strong at 49.8%. Research and development expenses increased slightly by 5.5% to ¥1.700 billion, while selling, general, and administrative costs rose modestly by 1.0% to ¥1,022 billion.
The company's core earnings per share (EPS) reached ¥274.02, reflecting a 13.6% improvement from the prior year. In addition to regular dividends, Chugai announced a special dividend of ¥75 per share to commemorate its centennial anniversary. The total dividend payout for the fiscal year includes a mid-year dividend of ¥125 and an end-of-year dividend of ¥72, bringing the combined dividend to ¥272 per share. Looking ahead, Chugai remains optimistic about its future prospects, citing favorable exchange rates and anticipated regulatory approvals for key products.
The company’s management highlighted the importance of ongoing innovation and strategic investments in research and development to sustain long-term growth.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing